Merrimack Pharmaceuticals, Inc. MACK NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

Merrimack Pharmaceuticals, Inc. (MACK) — Analyst outlook / Analyst consensus target is. Based on 11 analyst ratings, the consensus is bullish — 6 Buy, 4 Hold, 1 Sell.

MACK Analyst Ratings

Buy

Ratings

6 Buy

4 Hold

1 Sell

Based on 11 analysts giving stock ratings to Merrimack Pharmaceuticals, Inc. in the past 3 months

Rating breakdown

Buy

6 55%

Hold

4 36%

Sell

1 9%

55%

Buy

6 analysts

36%

Hold

4 analysts

Sell

1 analysts

People Also View

FOLD

Amicus Therapeutics, Inc.

$14.46

-0.03%

CLDX

Celldex Therapeutics, Inc.

$33.33

+2.27%

AGIO

Agios Pharmaceuticals, Inc.

$33.30

+0.45%

PBYI

Puma Biotechnology, Inc.

Eli Lilly and Company

Merrimack Pharmaceuticals, Inc. MACK NASDAQ

MACK Analyst Ratings

People Also View

Get Undervalued Stock Alerts